Reimbursement for CAR T-cell therapy liso-cel (Breyanzi) for aggressive lymphoma

The Dutch Healthcare Institute has advised the Minister of Health, Welfare and Sport to reimburse lisocabtagene maraleucel (liso-cel, Breyanzi) from the basic package for certain patients with aggressive lymphoma after price negotiations. The reason for this advice is the placement of the product in the lock.

Liso-cel is a form of CAR T-cell therapy that specifically targets B cells that express CD19. Reimbursement has been requested for adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who have received at least 2 previous systemic treatments.

The minister has placed liso-cel in the lock for expensive medicines. A medicine in this slot is only eligible for reimbursement from the basic package if there is a positive package recommendation from the Healthcare Institute, agreements have been made for appropriate use, and a price reduction has been successfully negotiated.

The Healthcare Institute advises the Minister of Health, Welfare and Sport to reimburse liso-cel from the basic health insurance package after price negotiations. However, only if the net price is not higher than the lowest net price of axi-cel or tisa-cel. The price for treatment must also be lower if more medicines become available for the same indication.

Source:

Healthcare Institute of the Netherlands